Held by
0
portfolios on TandT
Bookmarked by
0
users
Avg position size
—
of holders' portfolios
13F filers
0
institutions
52-week range
$0.29 – $0.42
41% from low
Exchange
OTC Link
OS
Click rows below (any statement) to add/remove series. Selection stays as you switch tabs.
| 2018 | 2019 | 2020 | 2021 | 2022 | 2023 | 2024 | 2025 | |
|---|---|---|---|---|---|---|---|---|
| Revenue | $42.5M | $44.9M | $65.3M | $81.8M | $66.6M | $52.6M | $50.2M | $51.6M |
| Cost of revenue | $19.8M | $21.2M | $27.8M | $42.5M | $42.6M | $28.8M | $28.7M | $25.1M |
| Gross profit | $22.7M | $23.7M | $37.4M | $39.4M | $24.0M | $23.9M | $21.5M | $26.5M |
| Gross margin | 53.3% | 52.8% | 57.3% | 48.1% | 36.1% | 45.3% | 42.8% | 51.4% |
| R&D | $1.6M | $2.3M | $1.4M | $1.4M | $1.5M | $1.8M | $1.3M | $1.4M |
| Operating income | $12.2M | $5.8M | $16.9M | $21.7M | $1.9M | $2.1M | $6.5M | $7.0M |
| EBITDA | $16.2M | $10.0M | $20.0M | $27.4M | −$2.2M | $7.7M | $11.2M | $12.6M |
| Net income | $10.1M | $3.7M | $11.1M | $15.9M | −$9.6M | $2.4M | $6.2M | $2.1M |
| Net margin | 23.8% | 8.2% | 17.0% | 19.4% | -14.4% | 4.5% | 12.4% | 4.1% |
| EPS (diluted) | 0.02 | 0.01 | 0.02 | 0.03 | -0.02 | 0.01 | 0.01 | 0.00 |
Annual figures · source: Financial Modeling Prep
| Year | Est. revenue | Est. EPS | EPS range | # Analysts |
|---|---|---|---|---|
| 2026 | $53M | $0.02 | $0.02–$0.02 | 1 |
| 2027 | $57M | $0.02 | $0.02–$0.02 | 1 |
| 2028 | $61M | $0.02 | $0.02–$0.02 | 1 |
| 2029 | $64M | $0.02 | $0.02–$0.02 | 1 |
Forward consensus · source: Financial Modeling Prep
EKF DIAGNOSTICS HLDGS ORD
No one on the platform currently holds EKDHF.
No tracked institution reports a position in EKDHF as of their last filing.
| Ex-date | Per share | Pay date |
|---|---|---|
| 2023-11-02 | $0.0120 | 2023-12-01 |
No one on the platform has traded EKDHF yet.
| $143M |
| — |
| BRNHFBroncus Holding Corporation | $0.08 | +0.00% | $42M | — |
| CMXCCell MedX Corp. | $0.42 | — | $126M | — |
Source: Financial Modeling Prep · peers by sector/industry
No recent Form 4 filings on EDGAR — either no insider transactions reported recently or this isn't a SEC-registered issuer.
Trading at NaN× earnings vs its 60.2× historical median P/E.
Fair value ≈ $-1.03 · price $0.35 today
Fair-value line = the stock's median historical P/E × earnings. Price below the orange line = cheap vs its own history; above = expensive. Not investment advice.